Table 1.
Characteristics of HIV-patients according to origin and stages of tuberculosis infection
| TB-endemic countries (N = 217) | TB low-endemic countries (N = 81) | |||||||
|---|---|---|---|---|---|---|---|---|
| LTBI | Prior TB* | Active TB | Prior LTBI | No TB | LTBI | Prior TB | No TB | |
| (N = 60) | (N = 23) | (N = 7) | (N = 4) | (N = 123) | (N = 4) | (N = 3) | (N = 74) | |
| Age | ||||||||
| Median (IQR) | 37 (31–41) | 41 (36–46) | 43 (39–48) | 45 (37–49) | 36 (31–42) | 44 (40–47) | 50 (43–60) | 53 (46–60) |
| Gender | ||||||||
| Female N (%) | 36 (60) | 11 (48) | 3 (43) | 2 (50) | 87 (71) | 2 (50) | 1 (67) | 19 (26) |
| Male N (%) | 24 (40) | 12 (52) | 4 (57) | 2 (50) | 36 (29) | 2 (50) | 2 (33) | 55 (74) |
| Years of stay in Norway | ||||||||
| Median (IQR) | 5 (2–8) | 7 (3–11) | 5 (1–6) | 4 (3–5) | 7 (4–10) | n/a | n/a | n/a |
| Years of HIV infection | ||||||||
| Median (IQR) | 3 (2–7) | 8 (3–10) | 7 (3–10) | 6 (5–8) | 6 (3–9) | 16 (9–20) | 6 (3–23) | 6 (3–11) |
| Nadir CD4 cells/μl | ||||||||
| Median (IQR) | 270 (170–488) | 80 (40–190) | 190 (50–290) | 92 (81–190) | 188 (87–290) | 135 (90–180) | 101 (100–230) | 192 (90–354) |
| CD4 cells/μl at enrolment | ||||||||
| Median (IQR) | 472 (342–638) | 340 (240–430) | 270 (50–340) | 541 (442–608) | 408 (276–590) | 465 (375–595) | 320 (310–560) | 468 (312–690) |
| ART at enrolment N (%) | 28 (47) | 17 (74) | 5 (71) | 4 (100) | 88 (71) | 4 (100) | 3 (100) | 49 (66) |
| Exposure to TB | 16 (27) | 1 (4) | 2 (29) | 2 (50) | 8 (6) | 0 | 1 (33) | 6 (8) |
| TST positive (%) | 30 (60)1 | 8 (47)3 | 1 (25)5 | 07 | 10 (10)8 | 010 | 1 (50)12 | 2 (5)14 |
| TST mm (median-IQR) | 10 (0–15) | 3 (0–15) | 0 (0–5) | 0 (0–0) | 0 | 0 (0–1) | 11 (0–22) | 0 |
| QFT positive (%) | 56 (93) | 9 (35) | 6 (86) | 1 (25) | 0 | 4 (100) | 1 (33) | 0 |
| QFT IU/ml (median-IQR) | 2.00 (0.56–6.20) | 0.34 (0.34–1.88) | 6.33 (0.81–10) | 10 (10–10) | 0.34 | 0.91 (0.49–5.63) | 0.34 (0.34–10) | 0.34 |
| TSPOT positive (%) | 20 (87)2 | 6 (50)4 | 3 (60)6 | …. | 09 | 011 | 013 | 015 |
| TST/QFT discordance N (%) | 22 (44) | 5 (29) | 2 (50) | 0 | 10 (10) | 3 (60) | 0 | 2 (5) |
| TST-/QFT+ | 19 | 2 | 2 | 0 | 0 | 3 | 0 | 0 |
| TST+/QFT- | 3 | 3 | 0 | 0 | 10 | 0 | 0 | 2 |
TB: tuberculosis. LTBI: latent TB infection. ART: antiretroviral therapy. QFT: QuantiFERON TB Gold. TSPOT: T-SPOT.TB. n/a: not applicable. *Excludes 2 diagnosed with LTBI and 4 diagnosed with current active TB. 1TST available in 50 LTBI pasients from TB-endemic countries. 2TSPOT available in 23 LTBI pasients from TB-endemic countries. 3TST available in 17 patients with prior TB from TB-endemic countries. 4TSPOT available in 12 patients with prior TB from TB-endemic countries. 5 TST results available in 4 patients with active TB. 6 TSPOT results available in 5 patients with active TB. 7TST results available in 2 patients with prior LTBI. 8 TST available in 96 “no TB” patients from TB-endemic countries. 9TSPOT available in 44 “no TB” patients from TB-endemic countries. 10TST available in 3 LTBI pasients from TB low-endemic countries. 11TSPOT available in 2 LTBI pasients from TB low-endemic countries. 12TST available in 2 patients with prior TB from TB low-endemic countries. 13 TSPOT available in 2 patients with prior TB from TB low-endemic countries. 14TST available in 43 “no TB” patients from TB low-endemic countries. 15TSPOT available in 28 “no TB” patients from TB low-endemic countries.